Monopar Therapeutics shares drop more than 7% after stock trades below short-term moving averages

Traders Union
All News
Stocks
Monopar therapeutics slides 7.26% today

Highlights

Shares of Monopar Therapeutics dropped 7.26% to $89.61 with price action pinned near the session’s low.
Technical indicators confirm short- and medium-term selling pressure, with the stock trading below key short-term averages and oversold signals mounting.
For the next 5 days, consolidation is the baseline scenario within a range of $84.4275 to $94.7925, with 59% probability of further downside.

Anton Kharitonov, expert at Traders Union, sees Monopar Therapeutics stuck in a persistent short-term downtrend. He notes the failure to reclaim the 20-day and 50-day moving averages points to systemic weakness. Oversold indicators signal that sellers still dominate, despite deep technical exhaustion. The lack of supportive news flow leaves sentiment fragile and directionless. "Until we see stabilization or a positive catalyst, I remain cautious on the stock's outlook," he says.

Viktoras Karapetjanc, expert at Traders Union, highlights that the long-term bullish structure remains intact for Monopar Therapeutics. He emphasizes the stock is still well above its 200-day average, which preserves favorable prospects for future growth. While short-term volatility is pronounced, the probability of consolidation opens opportunities for accumulation. He expects renewed upside if resistance at $94.7925 is cleared. "The underlying trend invites constructive positioning as buyers could regain control soon," he states.

Jainam Mehta, market strategist, views the setup as a tactical range between $84.4275 and $94.7925 with weak momentum indicators. He notes the oversold RSI and CCI may create contrarian opportunities if price action stabilizes. For Mehta, price holding above the 200-day average is key for the long-term view. "I would watch for a potential breakout above $94.7925 as a tactical trade," he says.

Short-term selling persists as oversold signals intensify

Monopar Therapeutics is trading below its 20-day and 50-day moving averages at $109.2518 and $111.1536, respectively, but remains above its 200-day moving average of $76.2336. This setup indicates ongoing short- and medium-term selling pressure, although the long-term trend stays bullish. The immediate resistance sits at $94.005, with near-term support at $84.4275. Momentum is weak: MACD signals a sell, ADX remains neutral, and RSI at 33.99 approaches oversold territory. Stochastic RSI and CCI also show oversold signals, while BBP at -7.07 highlights persistent seller control and deep oversold levels.

Earlier, analysts noted that Monopar Therapeutics was exhibiting persistent short- and medium-term bearish momentum while maintaining long-term trend support. The current analysis continues to validate this outlook, with the key focus now on whether the $84.4275 support level holds amid prevailing downside risk.

Source of Data: MNPR Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.